UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics
Mkt cap £154n – shares down 6% on the day
Audited (not preliminary) results for the year ended 30 June 2018.
Congratulations to Bioventix for the timely reporting of their audited financial statements.
The highlights make great reading:
Revenue up 21% to £8.8m - revenue benefitted from a back royalty of £0.8m, notwithstanding it’s still excellent growth. Profit before tax up 19% to £6.9m – not often that you see a 78% pre-tax margin! Cash up £0.8m to £7.0m, even after the increased dividend Special dividend of 55p per share (2017: 40p)
The results statement came with a nice introduction to the business, as follows:
Bioventix creates and supplies antibodies for use in blood testing machines that are used in hospitals and other labs around the world. These blood testing machines are…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY
Bioventix is a business engaged in the creation and engineering of antibodies. It was incorporated in 2003, and began trading…